Assignee
NIKANG THERAPEUTICS INC
US·13 granted patents·13 pending applications·15 citations·filing 2019–2025
Top patents by PatentIndex Score
26 records- 0197US11267782B2Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitorsNIKANG THERAPEUTICS INC·Filed 2021·Granted Mar 8, 2022·6 cites·26 claims
- 0296US11753366B2Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·3 cites·6 claims
- 0396US11420936B2Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseasesNIKANG THERAPEUTICS INC·Filed 2022·Granted Aug 23, 2022·2 cites·15 claims
- 0493US11634382B2Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrileNIKANG THERAPEUTICS INC·Filed 2021·Granted Apr 25, 2023·2 cites·37 claims
- 0587US11518772B2Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitorsNIKANG THERAPEUTICS INC·Filed 2020·Granted Dec 6, 2022·1 cites·10 claims
- 0687US2025340508A1Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0785US12391642B2Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·19 claims
- 0883US11459340B2Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitorsNIKANG THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·1 cites·8 claims
- 0981US12264167B2Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitorsNIKANG THERAPEUTICS INC·Filed 2022·Granted Apr 1, 2025·0 cites·11 claims
- 1081US2025361203A1Processes of making 3-fluoro-5-(((1s,2ar)-1,3,3,4,4 pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)benzonitrile and polymorphs thereofNIKANG THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1178US12435034B2Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrileNIKANG THERAPEUTICS INC·Filed 2023·Granted Oct 7, 2025·0 cites·20 claims
- 1277US12415779B2Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereofNIKANG THERAPEUTICS INC·Filed 2022·Granted Sep 16, 2025·0 cites·34 claims
- 1376US2021347729A1Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1474US2022380302A1Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseasesNIKANG THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1570US2020361855A1Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1665US2024287100A1Alkylidene derivatives as kras inhibitorsNIKANG THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1764US2026021095A1BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAYNIKANG THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1864US2025367193A1Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathwayNIKANG THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1963US12331026B2Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitorsNIKANG THERAPEUTICS INC·Filed 2023·Granted Jun 17, 2025·0 cites·37 claims
- 2062US2024408047A1Hypoxia inducible factor-2(alpha) inhibitors for the treatment of bladder cancerNIKANG THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2159US2024166669A1Quinazoline amine derivatives as kras inhibitorsNIKANG THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2259US2025018049A1Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathwayNIKANG THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2354US2022274914A1Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2452US12077506B2Indane derivatives as hypoxia inducible factor-2(α) inhibitorsNIKANG THERAPEUTICS INC·Filed 2019·Granted Sep 3, 2024·0 cites·23 claims
- 2551US12171741B22,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitorsNIKANG THERAPEUTICS INC·Filed 2019·Granted Dec 24, 2024·0 cites·23 claims
- 2651US2022177487A1Fused polycyclic pyridone compounds as influenza virus replication inhibitorsNIKANG THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NIKANG THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →